Literature DB >> 25322730

Successful treatment of nail lichen planus with alitretinoin: report of 2 cases and review of the literature.

Adel Alsenaid1, Irina Eder, Thomas Ruzicka, Markus Braun-Falco, Ronald Wolf.   

Abstract

BACKGROUND: Treatment of nail lichen planus (LP) is difficult and an optimal therapy is lacking.
OBJECTIVE: To report additional cases to the scant existing literature to learn more about therapeutic options for nail LP.
METHODS: A regimen of 30 mg alitretinoin daily in 2 cases of nail LP over a period of 9 and 8 months, respectively.
RESULTS: In either case, nail changes showed marked improvement under oral alitretinoin therapy within 2 and 4 months, respectively. In both patients, affected nails with end-stage destructive pterygium were resistant to any previously applied therapy.
CONCLUSION: Alitretinoin is an effective treatment option for nail LP. We recommend early diagnosis of nail LP and early initiation of systemic therapy with alitretinoin to prevent the development of pterygium and permanent nail damage. However, further clinical studies are needed to establish reliable guidelines for nail LP therapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25322730     DOI: 10.1159/000365655

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  4 in total

1.  Alitretinoin Treatment for Gefitinib-Induced Paronychia.

Authors:  Soo Young Lee; Jin-Wou Kim; Dong Soo Yu; Young Bok Lee
Journal:  Ann Dermatol       Date:  2019-05-01       Impact factor: 1.444

2.  Successful Treatment of Nail Lichen Planus with a Lacquer Containing Urea, Keratinase, and a Retinoid Molecule: Report of 10 Cases.

Authors:  Massimo Milani; Liboria Adamo
Journal:  Case Rep Dermatol       Date:  2022-03-21

3.  Alitretinoin in Dermatology-An Update.

Authors:  Aditya Kumar Bubna
Journal:  Indian J Dermatol       Date:  2015 Sep-Oct       Impact factor: 1.494

4.  Recommendations for treatment of nail lichen planus during the COVID-19 pandemic.

Authors:  Jose W Ricardo; Shari R Lipner
Journal:  Dermatol Ther       Date:  2020-06-04       Impact factor: 3.858

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.